Skip to main content
EJNMMI Research
Figure 2 | EJNMMI Research

Figure 2

From: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model

Figure 2

Graphs showing percentage of rats having primary tumors and metastases, and mean body weight of animals. (A) Percentage of (LEW/SsNHsd Lewis) rats with primary tumors reaching the maximum size of >6 cm3 that underwent surgery afterwards to remove the tumor. The control group received saline. RAD001 therapy started at day 4 (5 mg/kg administered twice weekly). 177Lu-DOTATATE (125 MBq) was administered at day 1. (B) Percentage of (LEW/SsNHsd Lewis) rats developing metastases in each group. (C) Mean body weight of animals in the control group (black line) and of the rats treated with either RAD001 or a combination of RAD001 and 177Lu-DOTATATE that did not develop metastases (blue line) versus the body weight of rats treated with RAD001 or a combination of RAD001 and 177Lu-DOTATATE that developed metastases (red line).

Back to article page